Literature DB >> 24576475

Silent reintroduction of wild-type poliovirus to Israel, 2013 - risk communication challenges in an argumentative atmosphere.

E Kaliner1, J Moran-Gilad, I Grotto, E Somekh, E Kopel, M Gdalevich, E Shimron, Y Amikam, A Leventhal, B Lev, R Gamzu.   

Abstract

Israel has been certified as polio-free by the World Health Organization and its routine immunisation schedule consists of inactivated poliovirus vaccine (IPV) only. At the end of May 2013, the Israeli Ministry of Health (MOH) has confirmed the reintroduction of wild-type poliovirus 1 into the country. Documented ongoing human-to-human transmission necessitated a thorough risk assessment followed by a supplemental immunisation campaign using oral polio vaccine (OPV). The unusual situation in which ongoing poliovirus transmission was picked up through an early warning system of sewage monitoring without active polio cases, brought about significant challenges in risk communication. This paper reviews the challenges faced by the MOH and the communication strategy devised, in order to facilitate and optimise the various components of the public health response, particularly vaccination. Lessons learned from our recent experience may inform risk communication approaches in other countries that may face a similar situation as global polio eradication moves towards the 'End game'.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24576475     DOI: 10.2807/1560-7917.es2014.19.7.20703

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  13 in total

1.  Evidence of cryptic incidence in childhood diseases.

Authors:  Christian E Gunning; Matthew J Ferrari; Erik B Erhardt; Helen J Wearing
Journal:  Proc Biol Sci       Date:  2017-08-30       Impact factor: 5.349

2.  Factors associated with COVID-19 vaccination acceptance among industrial workers in the post-vaccination era: a large-scale cross-sectional survey in China.

Authors:  Di Yin; Hongbiao Chen; Zhaomin Deng; Yue Yuan; Musha Chen; He Cao; Xiaofeng Zhou; Jingwei Luo; Wei Zhang; Zihao Gu; Ziyu Wen; Caijun Sun
Journal:  Hum Vaccin Immunother       Date:  2021-10-29       Impact factor: 3.452

3.  Addressing barriers to vaccine acceptance: an overview.

Authors:  Noni E MacDonald; Robb Butler; Eve Dubé
Journal:  Hum Vaccin Immunother       Date:  2017-11-29       Impact factor: 3.452

4.  Socioeconomic status and vaccine coverage during wild-type poliovirus emergence in Israel.

Authors:  B Binyaminy; N Bilenko; E J Haas; I Grotto; M Gdalevich
Journal:  Epidemiol Infect       Date:  2016-05-04       Impact factor: 4.434

5.  Between individualism and social solidarity in vaccination policy: the case of the 2013 OPV campaign in Israel.

Authors:  Hagai Boas; Anat Rosenthal; Nadav Davidovitch
Journal:  Isr J Health Policy Res       Date:  2016-12-21

6.  Social media as a platform for health-related public debates and discussions: the Polio vaccine on Facebook.

Authors:  Daniela Orr; Ayelet Baram-Tsabari; Keren Landsman
Journal:  Isr J Health Policy Res       Date:  2016-11-10

7.  Lessons learned from the 2009-2010 H1N1 outbreak for the management of the 2013 silent polio outbreak.

Authors:  Iftach Sagy; Paula Feder-Bubis; Victor Novack; Tal Peleg-Sagy; Dan Greenberg
Journal:  BMC Infect Dis       Date:  2018-05-29       Impact factor: 3.090

8.  Intervention programs to increase influenza vaccination in Israel: which is the preferred one?

Authors:  Itamar Grotto; Rami Grefat
Journal:  Isr J Health Policy Res       Date:  2014-05-27

9.  Vaccine hesitancy: understanding better to address better.

Authors:  Dewesh Kumar; Rahul Chandra; Medha Mathur; Saurabh Samdariya; Neelesh Kapoor
Journal:  Isr J Health Policy Res       Date:  2016-02-01

10.  Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel.

Authors:  Rami Yaari; Ehud Kaliner; Itamar Grotto; Guy Katriel; Jacob Moran-Gilad; Danit Sofer; Ella Mendelson; Elizabeth Miller; Amit Huppert; E Anis; E Kopel; Y Manor; O Mor; L Shulman; R Singer; M Weil
Journal:  BMC Med       Date:  2016-06-23       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.